The Sino Biological R&D team has many years of experience in recombinant protein research and development. Over the years, our team has generated more than 6,000 recombinant proteins currently in stock covering most hot research areas such as immune checkpoints, antibody drug targets, CAR-T cell therapy targets, Fc receptors, influenza viral proteins and cytokines.
Exhibiting properties of high purity and validated bioactivity, Sino Biological recombinant proteins can support your scientific research from biopharmaceutical target discovery, protein structure and function analysis, cell therapy and recombinant enzyme characterization.
Sino Biological Inc. has developed a panel of recombinant antigens for SARS-CoV-2, including the N (nucleocapsid) protein, S protein, the S1 and S2 subunits of the S protein, and the RBD domain of the S proteins, Plpro protein.
Covers most hot immune checkpoint proteins including PD-1/ PD-L1 and CTLA-4 approved antibody drugs as well as prospective drug candidates such as TIM-3, CD47, GITR, etc.
Covers many hot cell therapy targets including CA9, EGFR and CD274 approved antibody drugs as well as prospective drug candidates such as CD19, CD33, IL3RA, EPCAM, TNFRSF17, etc.
Covers many antibody therapeutic targets including PD-1 and CD20 approved antibody drugs as well as prospective candidates such as PD-1, Her2 / ERBB2, EGFR, c-MET, IL6, IL17, TNF-alpha……
Covers the vast majority of Fc receptors across multiple species. Each receptor is verified for high bioactivity of binding to immunoglobulins.
Covers such classes as mAb drug targets, CAR-T related targets and vital Fc receptors. Each protein is confirmed for retention of functionality after biotinylation.
We offer one-stop services for recombinant protein production using our advanced protein expression platform technologies. Our full services include protein gene synthesis, protein codon optimization, protein expression vector design, large scale cell culture and fermentation, protein purification and protein quality control testing. We offer significant cost saving advantages and record speed in protein expression and bulk production. We also have extensive experience and expertise in the design and execution of various types of recombinant protein purification projects, with or without purification tags.
Sino Biological has in-house capacity to support 1000+ recombinant protein development and bulk production projects per year. We have the ability to perform rapid protein expression and purification process development and conduct process scaleup studies as needed. We can meet protein production requirements for both high-throughput and large-scale bulk production requirements. This unprecedented capacity can be utilized by our customers worldwide to accelerate their basic research, structural biology studies, product discovery initiatives and product development timelines.
We are committed to become the world's most cost-effective centralized lab for recombinant protein and monoclonal antibody bulk production to serve the life science community and biotech industry worldwide. We strive to change the way the life science research community and industry are generating and sourcing their proteins.